Acute increases in synaptic GABA detectable in the living human brain: A [11C]Ro15-4513 PET study

NeuroImage

Volumn 99, Issue , 2014, Pages 158-165

  Stokes, Paul R A ^a,b   Myers, Jim F ^a,c   Kalk, Nicola J ^a   Watson, Ben J ^c   Erritzoe, David ^a   Wilson, Sue J ^a,c   Cunningham, Vincent J ^d   Barros, Daniela Riano ^e   Hammers, Alexander ^e,f   Turkheimer, Federico E ^b   Nutt, David J ^a   Lingford Hughes, Anne R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f CERMEP IMAGERIE DU VIVANT   (France)

Author keywords

GABA; PET; Synaptic; Tiagabine

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; CARBON 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER C 11; GABA TRANSPORTER 1; PLACEBO; TIAGABINE; TRACER; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; AZIDE; BENZODIAZEPINE DERIVATIVE; GABRA1 PROTEIN, HUMAN; GABRA5 PROTEIN, HUMAN; NIPECOTIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; MEMORY; NEUROIMAGING; NORMAL HUMAN; NUCLEUS ACCUMBENS; PARAHIPPOCAMPAL GYRUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SPECTROSCOPY; SYNAPTIC MEMBRANE; TEST RETEST RELIABILITY; BRAIN; BRAIN CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; SYNAPSE;

ADULT; AZIDES; BENZODIAZEPINES; BRAIN; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEMORY; MIDDLE AGED; NIPECOTIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; PSYCHOMOTOR PERFORMANCE; RADIOPHARMACEUTICALS; RECEPTORS, GABA-A; SYNAPSES;

EID: 84903521807     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.05.035     Document Type: Article

References (52)

1. Ahn K., Gil R., Seibyl J., Sewell R.A., D'Souza D.C. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 2011, 36:677-683.
2. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
3. Azar N.J., Bangalore-Vittal N., Arain A., Abou-Khalil B.W. Tiagabine-induced stupor in patients with psychogenic nonepileptic seizures: nonconvulsive status epilepticus or encephalopathy?. Epilepsy Behav. 2013, 27:330-332.
4. Baulac S., Huberfeld G., Gourfinkel-An I., Mitropoulou G., Beranger A., Prud'homme J.F., Baulac M., Brice A., Bruzzone R., LeGuern E. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat. Genet. 2001, 28:46-48.
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
6. Braestrup C., Schmiechen R., Neef G., Nielsen M., Petersen E.N. Interaction of convulsive ligands with benzodiazepine receptors. Science 1982, 216:1241-1243.
7. Brunig I., Scotti E., Sidler C., Fritschy J.M. Intact sorting, targeting, and clustering of gamma-aminobutyric acid A receptor subtypes in hippocampal neurons in vitro. J. Comp. Neurol. 2002, 443:43-55.
8. Collinson N., Kuenzi F.M., Jarolimek W., Maubach K.A., Cothliff R., Sur C., Smith A., Otu F.M., Howell O., Atack J.R., McKernan R.M., Seabrook G.R., Dawson G.R., Whiting P.J., Rosahl T.W. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J. Neurosci. 2002, 22:5572-5580.
9. Crestani F., Keist R., Fritschy J.M., Benke D., Vogt K., Prut L., Bluthmann H., Mohler H., Rudolph U. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8980-8985.
10. Cunningham V.J., Jones T. Spectral analysis of dynamic PET studies. J. Cereb. Blood Flow Metab. 1993, 13:15-23.
11. Delforge J., Syrota A., Bendriem B. Concept of reaction volume in the in vivo ligand-receptor model. J. Nucl. Med. 1996, 37:118-125.
12. Doelken M.T., Hammen T., Bogner W., Mennecke A., Stadlbauer A., Boettcher U., Doerfler A., Stefan H. Alterations of intracerebral gamma-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies. Epilepsia 2010, 51:1477-1482.
13. During M., Mattson R., Scheyer R., Rask C., Pierce M. The Effect of Tiagabine HCI on Extracellular GABA Levels in the Human Hippocampus. Annual Meeting of the American Epilepsy Society, Seattle, Washington, USA 1992.
14. Egerton A., Demjaha A., McGuire P., Mehta M.A., Howes O.D. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010, 50:524-531.
15. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39:175-191.
16. Fink-Jensen A., Suzdak P.D., Swedberg M.D., Judge M.E., Hansen L., Nielsen P.G. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. 1992, 220:197-201.
17. Frankle W.G., Cho R.Y., Narendran R., Mason N.S., Vora S., Litschge M., Price J.C., Lewis D.A., Mathis C.A. Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology 2009, 34:624-633.
18. Frankle W.G., Cho R.Y., Mason N.S., Chen C.M., Himes M., Walker C., Lewis D.A., Mathis C.A., Narendran R. [C]Flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels. PLoS One 2012, 7:e32443.
19. Gousias I.S., Rueckert D., Heckemann R.A., Dyet L.E., Boardman J.P., Edwards A.D., Hammers A. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage 2008, 40:672-684.
20. Hadingham K.L., Wingrove P., Le B.B., Palmer K.J., Ragan C.I., Whiting P.J. Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors. Mol. Pharmacol. 1993, 43:970-975.
21. Hamandi K., Myers J., Muthukumaraswamy S. Tiagabine-induced stupor - more evidence for an encephalopathy. Epilepsy Behav. 2014, 31:196-197.
22. Hammers A., Allom R., Koepp M.J., Free S.L., Myers R., Lemieux L., Mitchell T.N., Brooks D.J., Duncan J.S. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 2003, 19:224-247.
23. Henry M.E., Jensen J.E., Licata S.C., Ravichandran C., Butman M.L., Shanahan M., Lauriat T.L., Renshaw P.F. The acute and late CNS glutamine response to benzodiazepine challenge: a pilot pharmacokinetic study using proton magnetic resonance spectroscopy. Psychiatry Res. 2010, 184:171-176.
24. Higgitt A., Lader M., Fonagy P. The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology (Berl) 1986, 89:395-403.
25. Hoftman G.D., Volk D.W., Bazmi H.H., Li S., Sampson A.R., Lewis D.A. Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. Schizophr. Bull 2013, (E-pub ahead of print). 10.1093/schbul/sbt178.
26. Kasugai Y., Swinny J.D., Roberts J.D., Dalezios Y., Fukazawa Y., Sieghart W., Shigemoto R., Somogyi P. Quantitative localisation of synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling. Eur. J. Neurosci. 2010, 32:1868-1888.
27. Kupers R., Danielsen E.R., Kehlet H., Christensen R., Thomsen C. Painful tonic heat stimulation induces GABA accumulation in the prefrontal cortex in man. Pain 2009, 142:89-93.
28. Lingford-Hughes A., Hume S.P., Feeney A., Hirani E., Osman S., Cunningham V.J., Pike V.W., Brooks D.J., Nutt D.J. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J. Cereb. Blood Flow Metab. 2002, 22:878-889.
29. Lingford-Hughes A., Reid A.G., Myers J., Feeney A., Hammers A., Taylor L.G., Rosso L., Turkheimer F., Brooks D.J., Grasby P., Nutt D.J. A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced alpha5 benzodiazepine receptors in limbic regions. J. Psychopharmacol. 2012, 26:273-281.
30. Loup F., Wieser H.G., Yonekawa Y., Aguzzi A., Fritschy J.M. Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. J. Neurosci. 2000, 20:5401-5419.
31. Makkar S.R., Zhang S.Q., Cranney J. Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. Neuropsychopharmacology 2010, 35:1625-1652.
32. Malizia A.L., Cunningham V.J., Bell C.J., Liddle P.F., Jones T., Nutt D.J. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry 1998, 55:715-720.
33. Michels L., Martin E., Klaver P., Edden R., Zelaya F., Lythgoe D.J., Luchinger R., Brandeis D., O'Gorman R.L. Frontal GABA levels change during working memory. PLoS One 2012, 7:e31933.
34. Miller L.G., Greenblatt D.J., Barnhill J.G., Summer W.R., Shader R.I. 'GABA shift' in vivo: enhancement of benzodiazepine binding in vivo by modulation of endogenous GABA. Eur. J. Pharmacol. 1988, 148:123-130.
35. Montgomery A.J., Thielemans K., Mehta M.A., Turkheimer F., Mustafovic S., Grasby P.M. Correction of head movement on PET studies: comparison of methods. J. Nucl. Med. 2006, 47:1936-1944.
36. Muthukumaraswamy S.D., Myers J.F., Wilson S.J., Nutt D.J., Lingford-Hughes A., Singh K.D., Hamandi K. The effects of elevated endogenous GABA levels on movement-related network oscillations. Neuroimage 2012, 66C:36-41.
37. Muthukumaraswamy S.D., Myers J.F., Wilson S.J., Nutt D.J., Hamandi K., Lingford-Hughes A., Singh K.D. Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex. Neuropsychopharmacology 2013, 38:1105-1112.
38. Myers J.F., Rosso L., Watson B.J., Wilson S.J., Kalk N.J., Clementi N., Brooks D.J., Nutt D.J., Turkheimer F.E., Lingford-Hughes A.R. Characterisation of the contribution of the GABA-benzodiazepine alpha1 receptor subtype to [(11)C]Ro15-4513 PET images. J. Cereb. Blood Flow Metab. 2012, 32:731-744.
39. Onoe H., Tsukada H., Nishiyama S., Nakanishi S., Inoue O., Langstrom B., Watanabe Y. A subclass of GABAA/benzodiazepine receptor exclusively localized in the limbic system. Neuroreport 1996, 8:117-122.
40. Richards D.A., Bowery N.G. Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus. Neurochem. Res. 1996, 21:135-140.
41. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 1999, 56:1043-1047.
42. Shin M.S., Park S.Y., Park S.R., Seol S.H., Kwon J.S. Clinical and empirical applications of the Rey-Osterrieth complex figure test. Nat. Protoc. 2006, 1:892-899.
43. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-428.
44. Smolnik R., Pietrowsky R., Fehm H.L., Born J. Enhanced selective attention after low-dose administration of the benzodiazepine antagonist flumazenil. J. Clin. Psychopharmacol. 1998, 18:241-247.
45. Spielberger C., Gorsuch R., Lushene P. Manual for the state-trait anxiety inventory 1970, Consulting Psychologist Press, Palo Alto, CA, USA.
46. Sybirska E., Seibyl J.P., Bremner J.D., Baldwin R.M., al-Tikriti M.S., Bradberry C., Malison R.T., Zea-Ponce Y., Zoghbi S., During M., et al. [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology 1993, 32:671-680.
47. Tallman J.F., Thomas J.W., Gallager D.W. GABAergic modulation of benzodiazepine binding site sensitivity. Nature 1978, 274:383-385.
48. Turkheimer F., Moresco R.M., Lucignani G., Sokoloff L., Fazio F., Schmidt K. The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]fluorodeoxyglucose: theory, implementation, and optimization procedures. J. Cereb. Blood Flow Metab. 1994, 14:406-422.
49. Tyacke R., Robinson E., Harris A., Lingford-Hughes A., Nutt D. Paradoxical effects of GABA on the in vivo uptake of [3H]Ro15-4513 in rat brain. British Association for Psychopharmacology Summer Meeting 2009, A21. Sage Science Press, Oxford, UK. D. Nutt, P. Blier (Eds.).
50. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., Krystal J.H., Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011, 191:122-127.
51. Weber O.M., Verhagen A., Duc C.O., Meier D., Leenders K.L., Boesiger P. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn. Reson. Imaging 1999, 17:417-425.
52. Wechsler D. The Wechster Memory Scale-Revised 1981, The Psychological Coporation, Harcourt Brace Jovanovich, Inc.